Neuroprotective Effects of Choline Alfoscerate in Experimental Diabetic Peripheral Neuropathy
Pharmaceuticals · 12.07.2026 · 19 (7) · 1076
DOI: 10.3390/ph19071076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 12.07.2026. Verfasst von Hyeri Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosystems Engineering, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Diabetic peripheral neuropathy (DPN) is a common and debilitating complication of diabetes mellitus characterized by progressive nerve degeneration and chronic neuropathic pain. Current therapies, including pregabalin, primarily provide symptomatic pain relief and have limited effects on preventing structural nerve damage. Therefore, the development of disease-modifying therapies remains an important unmet clinical need. This study investigated the neuroprotective effects of choline alfoscerate (CA) and its ability to attenuate mechanical hypersensitivity in a streptozotocin (STZ)-induced rat model of DPN.
Methods
Diabetes was induced in rats using STZ, and administration protocols were optimized to establish sustained hyperglycemia while minimizing mortality. CA treatment was initiated immediately after STZ administration and continued throughout the study period. Mechanical sensitivity was assessed using the von Frey test. Histopathological examination of sciatic nerves was performed to evaluate structural alterations, and serum biochemical and lipid parameters were analyzed to assess systemic metabolic changes.
Results
STZ-treated diabetic rats developed persistent hyperglycemia, mechanical allodynia, elevated serum triglyceride levels, and marked structural deterioration of sciatic nerve fascicles. CA treatment significantly increased paw withdrawal thresholds despite sustained hyperglycemia, indicating attenuation of mechanical hypersensitivity independent of glycemic control. Histopathological evaluation demonstrated reduced nerve fiber degeneration, attenuation of edema-like changes, and preservation of sciatic nerve architecture in CA-treated animals. In addition, CA significantly reduced serum triglyceride levels compared with diabetic controls.
Conclusions
CA attenuated mechanical hypersensitivity and exerted neuroprotective effects in STZ-induced diabetic rats. These benefits occurred independently of glucose lowering and were accompanied by improvements in nerve morphology and lipid metabolism. The findings suggest that CA may represent a promising therapeutic candidate for preserving peripheral nerve integrity and attenuating neuropathic progression in diabetic peripheral neuropathy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biosystems Engineering, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
- Department of Biomedical Sciences, School of Medicine, Inha University, Incheon 22212, Republic of Korea.
- Biomedical Research Institute, H+ Yangji General Hospital, Seoul 08779, Republic of Korea.
- Institute for Clinical and Translational Research, Center for the Improvement of Mentored Experiences in Research, University of Wisconsin-Madison, Madison, WI 53705, USA.
ORCID-Profile: Namhyun Chung, Woon Kyu Lee
Zitieren
APA
Lee, H., Park, H. W., Kim, H. G., Hyun, S. H., Chung, N., & Lee, W. K. (2026). Neuroprotective Effects of Choline Alfoscerate in Experimental Diabetic Peripheral Neuropathy. Pharmaceuticals, 19(7), 1076. https://doi.org/10.3390/ph19071076
Vancouver
Lee H, Park HW, Kim HG, Hyun SH, Chung N, Lee WK. Neuroprotective Effects of Choline Alfoscerate in Experimental Diabetic Peripheral Neuropathy. Pharmaceuticals. 2026;19(7):1076. doi:10.3390/ph19071076
BibTeX
@article{Lee2026,
author = {Lee, Hyeri and Park, Hye Won and Kim, Hyung-Gun and Hyun, So Hee and Chung, Namhyun and Lee, Woon Kyu},
title = {Neuroprotective Effects of Choline Alfoscerate in Experimental Diabetic Peripheral Neuropathy},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1076},
doi = {10.3390/ph19071076}
}
EUVIMED